518044-31-0

Basic information

• Product Name: Hydroxy-PEG3-t-butyl acetate
• Synonyms: Hydroxy-PEG3-t-butyl acetate;Hydroxy-PEG3-CH2CO2tBu;Hydroxy-PEG3-CH2COOtBu;HO-PEG3-CH2COOtBu;tert-butyl 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)acetate;OH-PEG3-CH2COOtBu;tert-butyl 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)acetate(WXPC0085)
• CAS NO: 518044-31-0
• Molecular Formula: C12H24O6
• Molecular Weight: 264.31536
• Mol File: 518044-31-0.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 351.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.071±0.06 g/cm3(Predicted)
• PKA: 14.36±0.10(Predicted)
• CAS DataBase Reference: Hydroxy-PEG3-t-butyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Hydroxy-PEG3-t-butyl acetate(518044-31-0)
• EPA Substance Registry System: Hydroxy-PEG3-t-butyl acetate(518044-31-0)

Safety Data

• Hazardous Substances Data: 518044-31-0(Hazardous Substances Data)

Usage

Description

Hydroxy-PEG3-CH2CO2tBu is a PEG linker containing a hydroxyl group with a t-butyl protected carboxyl group. The hydrophilic PEG spacer increases solubility in aqueous media. The hydroxyl group enables further derivatization or replacement with other reactive functional groups. The t-butyl protected carboxyl group can be deprotected under acidic conditions.

Upstream product

• 1443467-88-6 1-phenyl-2,5,8,11-tetraoxatridecan-13-oic acid tert-butyl ester 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 55489-58-2 triethylene glycol monobenzyl ether 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 

Downstream Products

• 1530778-24-5 t-butyl [2-(2-{2-[(4-methylbenzene-1-sulfonyl)oxy]ethoxy}ethoxy)ethoxy]acetate 
• 1618678-46-8 (2S,4R)-1-((S)-2-(tert-butyl)-20-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-15-methyl-4-oxo-6,9,12-trioxa-3,15-diazaicosan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1618678-45-7 (2S,4R)-1-((S)-2-(tert-butyl)-14-(4-(5-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)pentyl)piperazin-1-yl)-4-oxo-6,9,12-trioxa-3-azatetradecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 883564-93-0 13,13-dimethyl-11-oxo-3,6,9,12-tetraoxatetradecan-1-oic acid 

Relevant articles and documents

Heterocyclic compound and application thereof

The invention discloses a heterocyclic compound and application thereof. The invention provides a heterocyclic compound as shown in a formula I, or pharmaceutically acceptable salt thereof. The heterocyclic compound can be used for degrading ALK, c-Met and ROS proteins.

Di-substituted maleic amide linker for antibody drug conjugating and preparation method and use thereof

Provided in the present invention are a di-substituted maleic amide linker conjugated to an antibody and a preparation method and use thereof. In particular, the present invention conjugates a strongly cytotoxic active substance to a biomacromolecule thro

Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma

Traditional EZH2 inhibitors are developed to suppress the enzymatic methylation activity, and they may have therapeutic limitations due to the nonenzymatic functions of EZH2 in cancer development. Here, we report proteolysis-target chimera (PROTAC)-based EZH2 degraders to target the whole EZH2 in lymphoma. Two series of EZH2 degraders were designed and synthesized to hijack E3 ligase systems containing either von Hippel-Lindau (VHL) or cereblon (CRBN), and some VHL-based compounds were able to mediate EZH2 degradation. Two best degraders, YM181 and YM281, induced robust cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphomas, outperforming a clinically used EZH2 inhibitor EPZ6438 (tazemetostat) that was only effective against DLBCL. The EZH2 degraders displayed promising antitumor activities in lymphoma xenografts and patient-derived primary lymphoma cells. Our study demonstrates that EZH2 degraders have better therapeutic activity than EZH2 inhibitors, which may provide a potential anticancer strategy to treat lymphoma.